Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. It serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Revenue projections:

Revenue projections for JUBLPHARMA
Revenue projections for JUBLPHARMA

JUBLPHARMA's projected revenue growth suggests a favorable investment opportunity, particularly if confirmed by strong fundamental indicators. Investors might see the company's rising financial performance as a sign of future profitability and consider it a good time to invest in JUBLPHARMA.

Financial Ratios:

currentRatio 0.00000
forwardPE 27.33284
debtToEquity 51.97200
earningsGrowth 0.51400
revenueGrowth 0.08600
grossMargins 0.65617
operatingMargins 0.10765
trailingEps 39.53000
forwardEps 0.00000

JUBLPHARMA's Forward PE ratio suggests that the stock is priced appropriately in relation to its earnings. Not being overpriced, it offers room for growth, signaling potential upside for investors looking for a stock with reasonable valuation and growth potential.

Price projections:

Price projections for JUBLPHARMA
Price projections for JUBLPHARMA



Insider Transactions:

Insider Transactions for JUBLPHARMA
Insider Transactions for JUBLPHARMA


Jubilant Pharmova Limited saw 1 transactions to buy shares, with a market price of 1219.5999755859375.Throughout the period under consideration, there were no buy transactions.Jubilant Pharmova Limited has seen more sells at current price levels, which could indicate a potential decline. If this trend continues, investors may expect the stock's price to drop further as more people exit their positions.

Recommendation changes over time:

Recommendations trend for JUBLPHARMA
Recommendations trend for JUBLPHARMA


Analysts' buy bias toward Jubilant Pharmova Limited suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, Jubilant Pharmova Limited is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.